Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

116
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
116
Preventive Healthcare Services01:30

Preventive Healthcare Services

2.3K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
2.3K
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

2.0K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
2.0K
Infection01:20

Infection

11.6K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
11.6K
Standard Precaution01:26

Standard Precaution

3.2K
Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
3.2K
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

5.0K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) glossary: developing a lingua franca to facilitate data harmonization and cross-cohort analyses.

The British journal of dermatology·2021
Same author

National survey demonstrates significant variation in suture use for dermatological procedures.

Clinical and experimental dermatology·2020
Same author

Urothelial carcinoma initially presenting as vulvodynia.

Clinical and experimental dermatology·2020
Same author

Feasibility of a school-based exercise intervention for children with intellectual disability to reduce cardio-metabolic risk.

Journal of intellectual disability research : JIDR·2019
Same author

Pain in haemophilia: are we listening?

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Related Experiment Video

Updated: Apr 30, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

2.1K

Prophylaxis in real life scenarios.

K Fischer1, B Konkle, C Broderick

  • 1Van Creveldkliniek, University Medical Center Utrecht, Utrecht, The Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|April 26, 2014
PubMed
Summary

Prophylaxis is the standard for severe hemophilia A and B, preventing joint damage and bleeds. Individualized treatment plans, considering patient factors and new extended half-life products, optimize outcomes and quality of life.

Keywords:
bleedbypassing agentdosehaemarthrosisprophylaxissports

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

30.2K

Related Experiment Videos

Last Updated: Apr 30, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

2.1K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

30.2K

Area of Science:

  • Hematology
  • Orthopedics
  • Pharmacology

Background:

  • Severe hemophilia A and B management relies on prophylaxis to prevent hemarthroses and joint deterioration.
  • Current prophylaxis involves regular infusions of factor VIII or IX concentrates.
  • Secondary prophylaxis aims to preserve joint health after initial bleeding events.

Purpose of the Study:

  • To review the implementation of prophylaxis regimens for hemophilia A and B.
  • To discuss individualized prophylaxis strategies based on patient-specific factors.
  • To explore the impact of extended half-life products on prophylaxis protocols.

Main Methods:

  • Review of current prophylaxis strategies including primary, secondary, and event-driven approaches.
  • Discussion of factors influencing individualized prophylaxis: bleeding phenotype, pharmacokinetics, clinical scenario, and physical activity.
  • Consideration of the role of extended half-life clotting factor concentrates.

Main Results:

  • Prophylaxis significantly reduces the annual bleed rate and preserves joint structure and function.
  • Individualized prophylaxis enhances patient confidence, enabling a more active lifestyle.
  • Extended half-life products offer potential for modified infusion frequencies and improved adherence.

Conclusions:

  • Prophylaxis is essential for managing severe hemophilia A and B, improving joint health and quality of life.
  • Individualized treatment plans are crucial for optimizing prophylaxis effectiveness.
  • Advancements in clotting factor products are shaping the future of hemophilia prophylaxis.